These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 30674687)

  • 21. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
    Arbyn M; de Sanjosé S; Saraiya M; Sideri M; Palefsky J; Lacey C; Gillison M; Bruni L; Ronco G; Wentzensen N; Brotherton J; Qiao YL; Denny L; Bornstein J; Abramowitz L; Giuliano A; Tommasino M; Monsonego J
    Int J Cancer; 2012 Nov; 131(9):1969-82. PubMed ID: 22623137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
    Kim JJ
    Lancet Infect Dis; 2010 Dec; 10(12):845-52. PubMed ID: 21051295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
    Ezat SW; Aljunid S
    Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic HPV vaccines: new interventions for cancer control.
    Barr E; Sings HL
    Vaccine; 2008 Nov; 26(49):6244-57. PubMed ID: 18694795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.
    Dahlstrom KR; Fu S; Chan W; Shelal Z; Ramondetta LM; Lairson DR
    Pharmacoeconomics; 2018 Nov; 36(11):1355-1365. PubMed ID: 30019118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-based programs for vaccination against HPV.
    Elbasha EH; Dasbach EJ; Insinga RP; Haupt RM; Barr E
    Value Health; 2009; 12(5):697-707. PubMed ID: 19490561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis.
    Tejada RA; Vargas KG; Benites-Zapata V; Mezones-Holguín E; Bolaños-Díaz R; Hernandez AV
    Salud Publica Mex; 2017; 59(1):84-94. PubMed ID: 28423114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptability of HPV vaccines and perceptions related to genital warts and penile/anal cancers among men who have sex with men in Hong Kong.
    Wang Z; Mo PK; Lau JT; Lau M; Lai CH
    Vaccine; 2013 Sep; 31(41):4675-81. PubMed ID: 23845815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
    Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
    Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of prophylactic human papillomavirus vaccines on dermatology and venereology.
    Gross G
    G Ital Dermatol Venereol; 2008 Aug; 143(4):259-65. PubMed ID: 18833082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States.
    Prabhu V; Kathe N; Saxena K; Walia A; Markan R; Myers E; Einstein M
    Curr Med Res Opin; 2021 Sep; 37(9):1599-1607. PubMed ID: 34018457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
    Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA; Segal SV; Méndez JH
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Hum Vaccin Immunother; 2019; 15(7-8):1942-1948. PubMed ID: 31107640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
    Insinga RP; Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.